SINGULAIR (montelukast sodium) by Merck & Co. is leukotriene receptor antagonists [moa]. First approved in 2002.
Drug data last refreshed 2d ago
SINGULAIR (montelukast sodium) is an oral leukotriene receptor antagonist used to treat asthma and exercise-induced bronchoconstriction in patients 6 years and older. It works by blocking leukotriene receptors, which mediate inflammatory and bronchoconstrictor responses in asthma pathology. The granule formulation provides flexible dosing for pediatric and adult populations.
Brand is in decline phase with 12,250 annual Part D claims; commercial teams should expect portfolio reductions and transition planning.
Leukotriene Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
Worked on SINGULAIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSINGULAIR has minimal linked job openings, indicating a mature, stable-but-declining brand with limited growth hiring. Career opportunities are concentrated in sales force reductions and transition planning rather than expansion.